Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

AVDL

Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals PLC
Da:
Ordina per:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AVDL
DataOraFonteTitoloSimboloCompagnia
07/03/202522:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
07/03/202522:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
05/03/202514:00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:AVDLAvadel Pharmaceuticals PLC
03/03/202515:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AVDLAvadel Pharmaceuticals PLC
03/03/202513:00GlobeNewswire Inc.Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/02/202522:05GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3NASDAQ:AVDLAvadel Pharmaceuticals PLC
24/02/202514:00GlobeNewswire Inc.Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of SalesNASDAQ:AVDLAvadel Pharmaceuticals PLC
20/02/202522:05GlobeNewswire Inc.Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AVDLAvadel Pharmaceuticals PLC
14/02/202517:55Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVDLAvadel Pharmaceuticals PLC
22/01/202514:00GlobeNewswire Inc.Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and ReimbursementNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/01/202522:15GlobeNewswire Inc.Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ LaunchNASDAQ:AVDLAvadel Pharmaceuticals PLC
03/01/202514:00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8NASDAQ:AVDLAvadel Pharmaceuticals PLC
11/12/202414:00GlobeNewswire Inc.Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate TherapyNASDAQ:AVDLAvadel Pharmaceuticals PLC
14/11/202417:50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVDLAvadel Pharmaceuticals PLC
13/11/202414:00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/11/202413:00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
04/11/202414:00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12NASDAQ:AVDLAvadel Pharmaceuticals PLC
31/10/202412:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act LitigationNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/10/202420:02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/10/202414:00GlobeNewswire Inc.Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep AdvancesNASDAQ:AVDLAvadel Pharmaceuticals PLC
17/10/202415:41GlobeNewswire Inc.Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with NarcolepsyNASDAQ:AVDLAvadel Pharmaceuticals PLC
25/09/202414:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting AgentNASDAQ:AVDLAvadel Pharmaceuticals PLC
03/09/202414:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)NASDAQ:AVDLAvadel Pharmaceuticals PLC
20/08/202414:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral SuspensionNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202415:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202413:00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202414:00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8NASDAQ:AVDLAvadel Pharmaceuticals PLC
31/07/202422:05GlobeNewswire Inc.Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic HypersomniaNASDAQ:AVDLAvadel Pharmaceuticals PLC
27/06/202422:05GlobeNewswire Inc.Avadel Pharmaceuticals to Join Russell 3000® IndexNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202413:25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AVDLAvadel Pharmaceuticals PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AVDL